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Summary
In 2015, the international guidelines for diagnosis and
treatment of pulmonary hypertension were updated. Group
3 of the current classification includes pulmonary hyper-
tension associated with chronic obstructive pulmonary dis-
ease (COPD), interstitial lung disease, other pulmonary
diseases with restrictive and obstructive pattern, sleep-dis-
ordered breathing, alveolar hypoventilation disorders,
chronic exposure to high altitude, and developmental lung
diseases. Pulmonary hypertension associated with COPD
and interstitial lung disease is common but difficult to man-
age, as no long-term randomised controlled trial has been
conducted with specific pulmonary arterial hypertension
drugs in pulmonary hypertension associated with COPD,
and the one recent RCT in pulmonary hypertension as-
sociated with interstitial lung disease had to be stopped
early due to a possible increased risk of death and side ef-
fects in the treatment group. Specific treatment may thus be
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harmful and may worsen gas exchange as a result of pos-
sible recruitment of less oxygenised areas, i.e. by increas-
ing ventilation-perfusion mismatch. Management of pul-
monary hypertension patients with chronic lung diseases
requires careful evaluation and understanding of patho-
physiological mechanisms. Interestingly, mediators in PAH
and in fibrotic lung disease show some overlaps. Several
drugs effective in pulmonary arterial hypertensio have been
evaluated for anti-fibrotic treatment in interstitial lung dis-
ease, but until today without consistent success. While new
drugs with anti-fibrotic effects are now accessible, a spe-
cific evidence-based treatment for pulmonary hypertension
in interstitial lung disease or COPD with or without em-
physema is not yet available.
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Introduction
Pulmonary hypertension (PH) is defined by a mean pul-
monary artery pressure (mPAP) ≥25 mm Hg at rest meas-
ured during right heart catheterisation [1]. According to its
aetiology, PH is classified into five diagnostic groups [1].
Pulmonary arterial hypertension (PAH, group 1) describes
patients with precapillary PH, documented by a pulmonary
artery wedge pressure (PAWP) ≤15 mm Hg, a pulmonary
vascular resistance (PVR) >3 Wood units (WU) and the ab-
sence of other causes of pre-capillary PH, e.g. hypoxemia
or chronic parenchymal lung diseases (group 3) or chron-
ic thromboembolic disease (group 4) [1]. Chronic lung dis-
eases induce PH and, because they are very prevalent, may
also occur occasionally concomitant with PAH [1].
Group 3 PH includes chronic obstructive pulmonary dis-
ease (COPD) (group 3.1), interstitial lung disease (ILD,
group 3.2) (e.g. idiopathic pulmonary fibrosis [IPF]), other
lung diseases with mixed restrictive and obstructive pattern
(group 3.3, e.g. combined pulmonary fibrosis with em-
physema [CPFE]), sleep-disordered breathing (group 3.4),
alveolar hypoventilation syndromes, where hypercapnic
pulmonary vasoconstriction might have a role (group 3.5),
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chronic exposure to high altitude (group 3.6), and devel-
opmental abnormalities (group 3.7) [1]. Rare diseases in-
volving the lung, like sarcoidosis or pulmonary Langerhans
cell histiocytosis or lymphangioleiomyomatosis, are in-
cluded in group 5.2 with unclear or multifactorial mech-
anisms [1]. In the following review we will focus on PH
associated with the lung diseases COPD with or without
emphysema, interstitial lung diseases, ILD (as an example
IPF) and CPFE: PH group 3.1 to 3.3.
Pathophysiology of pulmonary
hypertension in parenchymal lung
diseases
Depending on the underlying lung disease, rarefication of
vessels (for example in emphysematous areas), paren-
chymal or vascular remodelling (for example in IPF), cy-
tokine release, hypoxaemia, and to some extent pulmonary
vascular abnormalities and thrombosis may contribute to
the development of PH. In contrast, in PH due to sleep-dis-
ordered breathing (3.4), alveolar hypoventilation disorders
(3.5) and chronic exposure to high altitude (3.6) hypox-
emia is present although lung parenchymal structure is pre-
served.
Physiologically, the entire cardiac output flows through the
pulmonary circulation and for a given cardiac output, pul-
monary resistance decreases by pulmonary arterial dilata-
tion or recruitment of under-recruited pulmonary vessels
[2]. While pulmonary arteries regulate their diameters and
are orchestrated by vasoconstrictive signalling, including
hypoxaemia-induced, resistance of alveolar capillaries is
mainly dependent on alveolar pressure and volume [2].
The hypoxic regulation (HPV or Euler-Liljestrand mechan-
ism) is relevant for pulmonary vasoconstriction in acute or
chronic pulmonary diseases such as pneumonia, COPD or
pulmonary embolism, which may all consecutively devel-
op into acute or chronic PH. This pathophysiological con-
sideration is particularly important to look at if vasodilat-
ing therapy targeting pulmonary arteries is considered in
patients with PH due to heterogeneous lung diseases. Vas-
odilating therapy may recruit areas with worse oxygenation
and may lead to worsening of hypoxia.
Hypoxaemia
Hypoxaemia, and on a cellular level hypoxia, is found in
advanced stages of all diseases of group 3 PH, although
in parenchymal diseases, destruction of lung tissue and re-
duction of total number of alveoli and vessels might addi-
tionally increase pulmonary arterial pressure. On one hand,
destroyed lung parenchyma has reduced blood flow and to
some extend increased pulmonary resistance; on the other
hand, hypoxia induces release of cytokines and mediators
which itself may lead to pulmonary vasoconstriction. The
physiological response to alveolar hypoxia helps to regu-
late blood flow to alveolar areas with high oxygen partial
pressure and is referred to as hypoxaemia-induced vaso-
constriction (HPV or Euler-Liljestrand mechanism). Al-
though the precise mechanisms of the regulation of vascu-
lar tone by hypoxaemia is still unknown, hypoxic effects
are thought to be mediated through reactive oxygen spe-
cies (ROS), redox couples and adenosine monophosphate-
activated kinases [3]. L-type calcium channels, nonspecific
cation channels and voltage-dependent potassium channels
are effectors of the hypoxia induced pulmonary vasocon-
striction [3].
Another mediator of hypoxia induced vasoconstriction, the
transcription factor hypoxia-inducible factor 1-alpha
(HIF-1α), contributes to hypoxia-mediated pulmonary vas-
cular remodelling and hypertension [4] and has been linked
to pulmonary hypertension in chronic fibrotic lung disease
[5]. Interestingly, vasonconstricting effects of hypoxaemia
are not linear: if hypoxaemia is very severe, hypoxaemic
pulmonary vasodilation will be observed [6].
Proliferative mediators in PH overlapping with fibrotic
pathways
In addition to hypoxia-induced signalling, increased cy-
tokines potentially promote vascular remodelling and pul-
monary (arterial) hypertension [7]. Similar to pulmonary
hypertension, fibrotic lung disease typically is character-
ised by increased cell proliferation and impaired apoptosis.
Lung fibroblasts differentiate into myofibroblasts and des-
troy normal lung tissue by accumulation and extracellular
matrix production. In pulmonary hypertension typically
smooth muscle cells of pulmonary arterial vessels show
increased proliferation and accumulation. Cytokines and
other signalling mediators orchestrate cell migration, pro-
liferation and survival, and can overlap between PH and
fibrotic lung disease. One important cytokine is endothelin,
a potent vasoconstrictor, which contributes to vascular re-
modelling in PH but also fibroblast accumulation in pul-
monary fibrosis [8].
Endothelin is a vasoactive peptide, with three subtypes,
ET-1, ET-2 and ET-3. It is expressed in several cell types
such as endothelial cells, epithelial cells, smooth muscle
cells and many more [8]. Endothelin binds to two G-protein
coupled receptors, endothelin receptor A and B [8]. En-
dothelin receptor B (specifically B1) is found on endotheli-
al cells, which are known to stimulate release of nitric
oxide and prostacyclin and thus vasodilation. Endothelin
receptor B (B2) mediates also vasoconstrictive effects. En-
dothelin A and B receptors are found on fibroblasts and
smooth muscle cells [8]. Endothelin receptor A is mainly
responsible for vasoconstriction [8]. Unselective or select-
ive endothelin receptor antagonism is a well-established
treatment option for patients with PAH [9]. For fibrotic dis-
eases, the role of endothelin has been extensively studied
in different models, and increased levels of endothelin have
been found in patients with IPF [8]. This double signalling
role of endothelin contributing to pulmonary hypertension
and fibrosis has led to several clinical trials investigating
endothelin antagonism in IPF or other idiopathic intersti-
tial pneumonia (IIP) patients, although none of them found
positive results so far [10–14].
Platelet derived growth factor (PDGF) has been associated
with pulmonary hypertension and lung fibrosis. PDGF is
found in several cell types including epithelial cells and
smooth muscle cells and acts via its two receptors PDGFα
and PDGFβ, with an intracellular tyrosine kinase domain
which can be inhibited by specific tyrosine kinase inhibit-
ors [7, 15]. PDGF activation promotes proliferation, migra-
tion and survival of smooth muscle cells in PAH and tar-
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geting PDGF has been considered a target in PH [7, 16].
In lung fibrosis, PDGF is a potent mitogen for fibroblasts
[17] and recognized pro-fibrotic mediator in different or-
gans [18].
Peroxisome proliferator-activated receptors (PPARγ) are
transcription factors involved in several physiological pro-
cesses such as adipogenesis, lipid metabolism and inflam-
mation. They regulate amongst others cell proliferation and
migration [7]. PPARγ agonists are beneficial to reduce PH
in different models [7]. In addition, PPARγ agonists oppose
the pro-fibrotic effects of transforming growth factor-beta
in fibrotic disease [19].
Transforming growth factor-beta (TGF-β) signalling regu-
lates various biological processes. Amongst others it has
potent effects on cell proliferation, apoptosis and differen-
tiation. PH can present with impaired TGF-β signalling due
to possible BMPR2 mutations [7]. In pulmonary fibrosis,
TGF-β signalling is considered the main pro-fibrotic medi-
ator, with effects on epithelial cells and fibroblasts [20]. It
is a potential inducer of differentiation of fibroblasts into
myofibroblasts, the key effector cells in fibrosis.
Epidemiology and clinical presentation
Pulmonary hypertension associated with chronic
obstructive pulmonary disease
COPD, as defined by the presence of pulmonary symptoms
including chronic cough, sputum production and the pres-
ence of an airway obstruction in spirometry, is a very com-
mon and mainly smoking-associated lung disease with an
estimated 350 000 cases living in Switzerland [21]. COPD
is a syndrome affecting several organ systems, including
peripheral muscles and the cardiovascular system. The
clinical presentation of COPD comprises a broad spectrum
of different phenotypes, characterised by various degrees
of lung emphysema and bronchiectasis, nonspecific symp-
toms and chronic disease progression over several years.
The prevalence of PH in COPD populations is clearly re-
lated to the severity of the underlying disease. If patients
are grouped according to the global initiative on obstruct-
ive lung diseases (GOLD), the prevalence of PH is around
5% for GOLD stage 1 or 2 (previously defined by 1-second
forced expiratory volume [FEV1] values >50% predicted),
25% in stage 3 (previously defined by FEV1 values
30–49% predicted) and almost 40% for stage 4 disease
(previously defined by FEV1 values <30% predicted) [22,
23]. The annual rate of increase in pulmonary pressure for
PH-COPD is thought to be relatively low at 0.39–0.65 mm
Hg/year [24]. In a cohort of 409 COPD GOLD 4 patients,
36% showed an mPAP of >25 mm Hg, but severe PH with
values >35 mm Hg was found in only 3.9% [25], and PH-
COPD with mPAP >40 mm Hg is rare [26].
During acute COPD exacerbations PAP has been shown
to increase about 16 mm Hg [27, 28]. However, PAP in-
creases only in a subgroup of COPD patients [29]. PH itself
might influence occurrence and severity of COPD exacer-
bation, as pulmonary artery enlargement has been associ-
ated with more severe COPD exacerbations [30].
Pulmonary hypertension associated with interstitial
lung disease
In comparison to COPD and emphysema, chronic fibrosing
interstitial lung diseases (ILD) are less common. Idiopathic
pulmonary fibrosis (IPF) is the most prevalent idiopathic
form of ILD, with prevalence estimates below 5000 cases
for Switzerland [31]. PH in IPF is also associated with ad-
vanced disease stages, (i.e. the severity of the underlying
IPF) and ranges from 8–15% [32, 33] at the time of dia-
gnosis to 35–45% [34, 35] for patients before lung trans-
plantation [23]. In IPF patients with mild-to-moderate re-
striction, who were recruited for a study of ambrisentan in
IPF patients (ARTEMIS-IPF), PH could be found in 14%
[36]. In patients with advanced or end-stage IPF, pulmon-
ary hypertension occurs in 30-50% or >60% respectively
[23]. However, in a cohort of patients awaiting lung trans-
plantation, only 9% had an mPAP of >40 mm Hg [37].
Lung functional or radiological impairment (high resolu-
tion computed tomography; HRCT) do not correlate well
with severity of PH [23, 25, 37]. The evolution of PH-
ILD is characterised by a progressive increase in mPAP of
0.17–3.8 mm Hg/month over time [34, 36]. PH represents
an independent predictor of survival for IPF [33].
Pulmonary hypertension associated with combined pul-
monary fibrosis and emphysema (CPFE) is a characteristic
combination of basal fibrotic and apical emphysematous
lung lesions affecting elderly male smokers, but the pre-
valence of the disease is rather low. CPFE has a typical
appearance on chest computed tomography and is charac-
terised by a severely impaired diffusion capacity but pre-
served lung volumes in functional testing. PH-CPFE is
found in up to 50% of patients, and 68% of PH-CPFE pa-
tients had mPAP >35 mm Hg [23, 38]. Presence of PH in
these patients is associated with worse outcome, with a me-
dian survival of less than 1 year in the subgroup of patients
with a PVR of >485 dyn·s·cm-5 [39].
Assessment and diagnosis
Patients with COPD (with or without emphysema), ILD or
CPFE and suspected PH require careful staging of the par-
enchymal lung disease. Lung disease assessment includes
lung functional testing by body plethysmography, diffusion
capacity measurements, arterial blood gas analysis, HRCT
of the chest and eventually bronchoscopy with broncho-
alveolar lavage and lung biopsy (if possible) to evaluate
lung parenchymal structure. Functional exercise tests in-
cluding cardiopulmonary exercise testing (CPET) and the
6 minutes walking test or sit-to-stand test [40] are part of
the assessment to diagnose and define disease stages accur-
ately. Non-invasive screening for PH-COPD, PH-ILD and
PH-CPFE is performed with echocardiography [1]. The
combination of the clinical and functional assessment with
brain natriuretic peptide measurements has been shown to
be useful to predict the presence of PH [41]. Nevertheless,
echocardiographic measurements might be inaccurate, es-
pecially in COPD patients [42]. However, while echocar-
diography and referral to an expert centre is recommended
if echocardiographic signs of severe PH are present (class
I, level C) in the recently updated European guidelines
[1], right heart catheterisation is discouraged for suspec-
ted PH in patients with lung diseases (class III, level C),
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unless therapeutic consequences are to be expected (e.g.
lung transplantation, alternative diagnosis such as PAH or
chronic thromboembolic pulmonary hypertension). Con-
tributing factors with an impact on treatment decisions are
to be searched for, including full night polysomnography
in the search for obstructive sleep apnoea or nocturnal hy-
poventilation, left heart catheterisation and coronary an-
giography in suspected coronary or left heart disease and
ventilation-perfusion scintigraphy to evaluate for venous
thromboembolism [1].
Sometimes it is difficult to differentiate whether lung dis-
ease and PH are coincidental or related. In suspected PH-
COPD or PH-ILD, previously proposed criteria [23] fa-
vouring PAH, with FEV1 >60% or forced vital capacity
(FVC) >70%, the absence of parenchymal abnormalities
on chest computed tomography and preserved breathing re-
serve with reduced oxygen pulse and a low cardiac output /
oxygen consumption ratio (CO/VO2 slope) are uncommon.
Most of the time patients show additional signs of paren-
chymal disease which complicates differentiation between
PAH or group 3 PH [23]. If PH is disproportionate to par-
enchymal lung disease the term “out of proportion” has
been previously used [43], but it has been suggested that
this term be abandoned because only a loss >80% of nor-
mal lung structure will provoke PH [23]. However, a re-
cent study showed that differentiation into mild and severe
lung disease as previously suggested [23] and illustrated in
table 1 has no impact on survival, but only severe PH-ILD
showed poor survival similar to the overall reduced surviv-
al of the ILD cohort (fig. 1 and fig. 2) [44]. The current
guidelines now categorise patients with parenchymal lung
diseases into three groups: lung disease without PH (mPAP
<25 mm Hg), lung disease with PH (mPAP ≥35 mm Hg)
and lung disease with severe PH (mPAP ≥ 35 mm Hg or
≥25 mm Hg in the presence of low cardiac output (<2.5
l/min/m2), not explained by other causes (table 2) [1, 23].
PH-ILD patients have an overall worse survival when com-
pared with other PH groups as observed in our national
Swiss registry for pulmonary hypertension [45].
Management
For PH-COPD, PH-ILD and PH-CPFE, recommendations
aim at optimal treatment of the underlying lung disease
for symptomatic improvement, improvement in quality of
life and in survival (class I, evidence level C) [1, 23]. The
mainstays for treatment recommendations for lung diseases
associated with PH have been listed previously [46].
Management of PH-COPD
For PH-COPD, smoking cessation, anti-obstructive treat-
ment and pulmonary rehabilitation are the most important
recommendations in all disease stages. As for exercise
training, it has recently been shown in a prospective ran-
domised controlled trial in patients with severe PH related
Figure 1
Survival for patients with pulmonary arterial hypertension,
pulmonary hypertension associated with CPFE, COPD,
emphysema and ILD. Survival for PH-ILD was significantly lower
compared with PAH (p <0.0001), PH-COPD (p = 0.0026) and PH-
CPFE (p = 0.05), while survival for other lung phenotypes did not
differ significantly.
CPFE = combined pulmonary fibrosis and emphysema; COPD =
chronic obstructive pulmonary disease; ILD = interstitial lung
disease; PAH = pulmonary arterial hypertension; PH = pulmonary
hypertension. (Reproduced with permission of the European
Respiratory Society © Eur Respir J. 2015;46(5):1378–89; DOI:
10.1183/13993003.02307-2014)
Table 1: Typical findings for lung function, radiology and exercise testing in pulmonary hypertension due to chronic lung diseases and in pulmonary arterial hypertension.
PH due to parenchymal lung diseases (Group 3) PAH (Group 1)
Lung function
FEV1
FVC or TLC
(% predicted)
<60% in PH – COPD
<70% in PH – ILD
(% predicted)
>60%
>70%
High resolution CT scan Presence of airway and / or parenchymal abnormalities No (or mild) abnormalities
CPET
Exercise limitation
Breathing reserve
Oxygen pulse
CO/VO2 slope
Oxygen saturation
CO2 during exercise
Ventilatory
Reduced
Near normal
Near normal
Mild desaturation
May increase
Cardiocirculatory
Preserved
Reduced
Low
Pronounced desaturation
No change / decrease
COPD = chronic obstructive pulmonary disease; CO/VO2 slope = cardiac output / oxygen consumption ratio; FEV1 = forded expiratory volume in 1 second; FVC = forced
vital capacity; ILD = interstitial lung disease; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; TLC = total lung capacity
Table 2: Current haemodynamic classification of pulmonary hypertension due to lung diseases (adapted from [1]).
Right heart catheterisation
COPD/ILD without PH Mean PAP <25 mm Hg
COPD/ILD with PH Mean PAP ≥25 mm Hg, but <35 mm Hg
COPD/ILD with severe PH Mean PAP >35 mm Hg, or ≥25 mm Hg with low cardiac output (CI <2.5 l/min/m2)
COPD = chronic obstructive pulmonary disease; ILD = interstitial lung disease; PAP = pulmonary arterial pressure; PH = pulmonary hypertension
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to inoperable chronic thromboembolic disease that pul-
monary resistance, that right ventricular function as well as
CPET parameters and walking distance improved with re-
habilitation [47]. Bronchodilators, in the form of long-act-
ing muscarinic antagonists (LAMAs) and long-acting beta
agonists (LABAs), often together with topical steroids, are
indicated in advanced symptomatic COPD, newly defined
GOLD class C (few symptoms, GOLD class 3–4 and/or
2 or more exacerbations per year) and D (more sympto-
matic, GOLD class 3–4 and/or 2 or more exacerbations
per year). Interestingly, in COPD patients, it has been ob-
served in a randomised trial that lung deflation is associated
with consistent beneficial effects on cardiac function and
pulmonary vasculature [48]. For advanced emphysematous
COPD with PH, endoscopic lung volume reduction may
be beneficial for both COPD and PH and is preferred over
surgical interventions because of the associated perioper-
ative risks in PH-COPD. As hypoxia triggers PH, supple-
mental oxygen at rest and upon exercise is recommended
(class I, evidence level C) [1]. Even though long-term ran-
domised controlled trials are not available, it has recently
been shown in a double-blind cross-over trial that nocturn-
al oxygen was able to improve right ventricular function
and walking distance after only 1 week of treatment in pa-
tients with precapillary PH and sleep-disturbed breathing
[49]. Lung transplantation for PH-COPD is an option if
other treatments fail, but post-transplant mortality seems to
be increased [50].
PAH specific drugs for PH-COPD
Many trials to treat PH in patients with COPD by drugs tar-
geting pulmonary vessel tone have been disappointing. In-
haled iloprost failed to improve exercise capacity in COPD
patients with PH [51]. The endothelin receptor antagonist
bosentan was not beneficial, but rather worsened arterial
oxygen pressure and health-related quality of life in COPD
patients without severe PH [52]. In contrast, sildenafil im-
proved pulmonary haemodynamics in COPD patients with
associated PH in a short term study, but long term invest-
igations are lacking [53]. In a more recent study, patients
with severe PH-COPD failed to improve functional class
Figure 2
Survival by severity of lung disease. For patients fulfilling the
definition of severe PH (mPAP >35 mm Hg or CI <2.0 l/min/m2) and
mild/ moderate lung disease (FEV1 >60%), there was no difference
in survival observed compared to severe PH/ severe lung disease
(Panel A). On the contrary, in patients with severe PH, the
underlying lung disease had a significant impact on survival (Panel
B). (Reproduced with permission of the European Respiratory
Society © Eur Respir J. 2015;46(5):1378–89; DOI: 10.1183/
13993003.02307-2014)
CPFE = combined pulmonary fibrosis and emphysema; COPD =
chronic obstructive pulmonary disease; ILD = interstitial lung
disease; LD = lung disease; PH = pulmonary hypertension
for dyspnoea or exercise performance [54]. In a pilot study,
riociguat, a soluble guanylate cyclase stimulator, improved
haemodynamics without impairing gas exchange in mild
PH-COPD, but this needs to be confirmed in a larger study
[55]. According to current knowledge and recommenda-
tions, specific drugs to induce vasodilatation of pulmonary
arteries are thus not a successful treatment option for pa-
tients with PH-COPD with or without emphysema at this
time [1]. Nevertheless, retrospective studies suggest that
some COPD patients with relevant PH (mPAP >30 mm Hg)
might profit from specific PH therapy, but additional stud-
ies need to be performed [56, 57].
Management of PH-ILD
For PH-COPD, smoking cessation, pulmonary rehabilit-
ation and supplemental oxygen to maintain saturations
above 90% at rest and upon exercise are recommended. In
patients with nonspecific interstitial lung diseases, a trial of
immunsuppressive therapy may be indicated. Anti-fibrot-
ic treatment with pirfenidone and nintedanib have recently
been approved for the treatment of IPF in Switzerland.
These drugs may potentially stabilise PH in fibrotic lung
disease by reduction of fibrosis progression. In addition,
novel anti-fibrotic treatments, specifically tyrosine kinase
inhibitors, target several of the overlapping signalling path-
ways between IPF and PH. Nintedanib inhibits VEGF and
PDGF tyrosine kinases [58]. Unclear are the effects of
VEGF inhibition by nintedanib in PH-IPF, as VEGF is be-
neficial for PH but might have pro-fibrotic effects [15].
Interestingly, tyrosine kinase inhibitors have previously
shown to be promising in PAH treatment [59]. However,
long-term safety data on treatment of PAH with imatinib
showed severe adverse events and imatinib is no longer ap-
proved for PAH treatment [60]. Whether novel anti-fibrotic
treatment impacts PH-IPF merits future investigation. Al-
though anti-fibrotic treatments are now able to slow down
disease progression in IPF, lung transplantation remains
the ultimate treatment for respiratory failure in selected
PH-IPF patients. A recent large retrospective analysis of
a transplant registry showed no difference in post-trans-
plant survival for IPF patients with or without associated
PH [61].
PAH specific drugs in IPF and PH-IPF
In fibrotic lung disease, several studies have investigated
the effects of specific PH treatment on PH and also on anti-
fibrotic effects of the underlying parenchymal lung disease.
For both aspects results have been disappointing. Some
very interesting preliminary studies with encouraging res-
ults led to the hypothesis that inhaled vasodilators for
fibrotic pulmonary disease may reach only well-ventilated
areas [62, 63], but until today, these observations have
not been published in larger studies. Bosentan, a dual en-
dothelin receptor antagonist, was well tolerated in patients
with IPF [10, 64], but failed to reduce progression of lung
fibrosis in a phase III trial [11, 23]. Ambrisentan, a select-
ive endothelin A antagonist, was investigated in a random-
ised clinical trial (ARTEMIS-IPF) for patients with IPF.
The study was stopped early for lack of benefit and high
likelihood of harm [12]. International guidelines recom-
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mend against the use of ambrisentan in IPF-associated PH
[65].
Recent data from a large prospective registry (COMPERA)
suggested short-term functional improvement in idiopathic
ILD patients with PH treated with any vasodilating therapy,
although impact on survival remains unclear [66]. Many
of the included patients were treated with a phosphodies-
terase-5 inhibitor (PDE5i), probably because a recent study
of IPF patients with low diffusion capacity (STEP-IPF)
suggested that ILD patients with PH might benefit from
treatment with sildenafil [67]. In a small study with selec-
ted lung fibrosis patients responding to NO vasodilating
treatment, in the acute setting sildenafil did not worsen gas
exchange due to dilatation of areas with increased hypox-
ic pulmonary vasoconstriction [68]. Retrospective studies
found possible survival benefits of patients with chronic
lung disease and severe PH under PDE5i therapy [69].
However, these results need to be confirmed in large pro-
spective controlled trials before this treatment may be re-
commended. In one recent phase II clinical study on the ef-
fects of riociguat in patients with PH associated with IIP
(RISE-IIP), riociguat was associated with a possible in-
creased risk for death and other serious adverse events as
compared with patients in the placebo group, and the study
was terminated by the independent drug monitoring com-
mittee [70].
Conclusion and current
recommendations
In COPD, ILD (IPF) and CPFE, PH is more prevalent in
advanced disease stages and is associated with more symp-
toms and worse prognosis. Current guidelines recommend
that patients with suspected PH-COPD, PH-ILD and PH-
CPFE are referred to expert centres with experience in as-
sessment and management of both diseases [23]. Echocar-
diography is recommended for the non-invasive diagnostic
assessment of suspected PH in patients with lung disease.
For clarification of the differential diagnosis, lung function
tests, chest HRCT, CPET and ventilation-perfusion scans
may be helpful. The optimal treatment of the underlying
lung disease including long-term oxygen therapy in pa-
tients with chronic hypoxaemia at rest or upon exertion is
recommended in patients with PH due to lung diseases.
Right heart catheterisation is not routinely recommended
for suspected PH-COPD and PH-ILD, unless therapeutic
consequences are to be expected. In summary, the use of
drugs approved for PAH is not recommended in patients
with PH due to chronic parenchymal lung diseases [1]. Fur-
ther studies focusing on novel therapeutic approaches are
therefore urgently needed.
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Figures (large format)
Figure 1
Survival for patients with pulmonary arterial hypertension, pulmonary hypertension associated with CPFE, COPD, emphysema and
ILD. Survival for PH-ILD was significantly lower compared with PAH (p <0.0001), PH-COPD (p = 0.0026) and PH-CPFE (p = 0.05), while
survival for other lung phenotypes did not differ significantly.
CPFE = combined pulmonary fibrosis and emphysema; COPD = chronic obstructive pulmonary disease; ILD = interstitial lung disease; PAH =
pulmonary arterial hypertension; PH = pulmonary hypertension, (Reproduced with permission of the European Respiratory Society © Eur Respir
J. 2015;46(5):1378–89; DOI: 10.1183/13993003.02307-2014).
Figure 2
Survival by severity of lung disease. For patients fulfilling the definition of severe PH (mPAP >35 mm Hg or CI <2.0 l/min/m2) and mild/
moderate lung disease (FEV1 >60%), there was no difference in survival observed compared to severe PH/ severe lung disease (Panel A). On
the contrary, in patients with severe PH, the underlying lung disease had a significant impact on survival (Panel B).
CPFE = combined pulmonary fibrosis and emphysema; COPD = chronic obstructive pulmonary disease; ILD = interstitial lung disease; LD =
lung disease; PH = pulmonary hypertension. (Reproduced with permission of the European Respiratory Society © Eur Respir J.
2015;46(5):1378–89; DOI: 10.1183/13993003.02307-2014).
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